# Genenta Science (GNTA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GNTA
## Company Profile
- Ticker: GNTA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Italy and listed in the U
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 0.9505 USD
- Market cap: 51900244.00000001 USD
- Last updated: 2026-09-03
## Business Overview
Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.
## Why The Stock Is Moving

As of Sep 3, 2026, GNTA closed down 2.82% at $0.9505. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in Italy and listed in the U.S. as an ADR, Genenta has a global cell-therapy profile.

## Business Model

The company depends on platform validation, clinical data, and the ability to turn engineered-cell science into oncology value.

## Landscape Position

Genenta is a high-catalyst cell-therapy name whose stock reacts to translational and clinical milestones.

## Future Catalysts

- Genenta’s catalysts are its onco-immunology platform and any data that show the hematology / solid-tumor approach can still advance. The company remains early and data-dependent.

## Recent News
- 2026-07-23 07:09 EST — [Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm](https://biopharmsignal.com/news/GNTA/genenta-backed-s-phia-high-tech-brings-aerospace-precision-inside-a-nuclear-fusi-b9c88834) — Source: Genenta Science
- 2026-07-22 08:00 EST — [Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results](https://biopharmsignal.com/news/GNTA/genenta-backed-s-phia-high-tech-reports-fiscal-year-2025-results-ab0d6779) — Source: Genenta Science
- 2026-04-23 11:00 EST — [Genenta signs Definitive Agreements with Sophia High Tech](https://biopharmsignal.com/news/GNTA/genenta-signs-definitive-agreements-with-sophia-high-tech) — Source: Genenta Science
- 2026-03-27 09:00 EST — [Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs](https://biopharmsignal.com/news/GNTA/genenta-evolving-into-saentra-forge-has-signed-a-binding-offer-with-sophia-high-tech-an-italian-company-manufacturing-critical-parts-for-europe-s-space-and-defense-programs) — Source: Genenta Science
- 2026-03-24 07:26 EST — [Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini](https://biopharmsignal.com/news/GNTA/genenta-evolving-into-saentra-forge-continues-to-evaluate-strategic-options-for-its-original-biotechnology-platform-derived-from-the-research-of-professor-luigi-naldini) — Source: Genenta Science